Administration of the same dose of epoetin-beta intravenously and subcutaneously to patients with renal anaemia

References

• Revised European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure. Nephrol Dial Transplant 2004;19(Suppl 2):ii1–47.
   PubMedGoogle Scholar
• KDOQI. National Kidney Foundation: KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis 2006;47(Suppl 3):S11–145.
   PubMedGoogle Scholar
• Muirhead N, Churchill DN, Goldstein M, Nadler SP, Posen G, Wong C, Comparison of subcutaneous and intravenous recombinant human erythropoietin for anemia in hemodialysis patients with significant comorbid disease. Am J Nephrol 1992;12:303–10.
   PubMed Web of Science ®Google Scholar
• Albitar S, Meulders Q, Hammoud H, Soutif C, Bouvier P, Pollini J. Subcutaneous versus intravenous administration of erythropoietin improves its efficiency for the treatment of anaemia in haemodialysis patients. Nephrol Dial Transplant 1995;10(Suppl 6):40–3.
   PubMedGoogle Scholar
• Canaud BC, Bennhold I, Delons S, Donnadleu P, Foret M, Franz H, What is the optimum frequency of administration of r-HuEPO for correcting anemia in hemodialysis patients? Dial Transplant 1995;24:306–29.
   Google Scholar
• Schaller R, Sperschneider H, Thieler H, Dutz W, Hans S, Voigt D, Differences in intravenous and subcutaneous application of recombinant human erythropoietin: a multicenter trial. Artif Organs 1994;18:552–8.
   PubMed Web of Science ®Google Scholar
• Virot JS, Janin G, Guillaumie J, Michel P, Dubot P, Chevet D, Must erythropoietin be injected by the subcutaneous route for every hemodialyzed patients? Am J Kidney Dis 1996;28:400–8.
   PubMed Web of Science ®Google Scholar
• Kaufman JS, Reda DJ, Fye CL, Goldfarb DS, Henderson WG, Kleinman JG, , for the Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. N Engl J Med 1998;339:578–83.
   PubMed Web of Science ®Google Scholar
• Fishbane S. Iron supplementation in renal anemia. Semin Nephrol 2006;26:319–24.
   PubMed Web of Science ®Google Scholar
• Macdougall IC, Chandler G, Elston O, Harchowal J. Beneficial effect of adopting an aggressive intravenous iron policy in hemodialysis unit. Am J Kidney Dis 1999;34(4):S40–6.
   PubMed Web of Science ®Google Scholar
• Besarab A, Amin N, Ahsan M, Vogel SE, Zazuwa G, Frinak S, Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol 2000;11:530–8.
   PubMed Web of Science ®Google Scholar
• Linde T, Furuland H, Wikström B. Effect of switching from subcutaneous to intravenous administration of epoetin-α in haemodialysis patients: result from a Swedish multicentre survey. Scand J Urol Nephrol 2005;39:329–33.
   PubMed Web of Science ®Google Scholar
• Leikis MJ, Kent AB, Becker GJ, McMahon LP. Haemoglobin response to subcutaneous versus intravenous epoetin alfa administration in iron-replete haemodialysis patients. Nephrology 2004;9:153–60.
   PubMed Web of Science ®Google Scholar
• Pizzarelli F, David S, Sala P, Icardi A, Casani A. Iron replete hemodialysis patients do not require higher EPO dosages when converting from subcutaneous to intravenous administration: results of the Italian Study on Erythropoietin Converting (ISEC). Am J Kidney Dis 2006;47:1027–35.
   PubMed Web of Science ®Google Scholar
• Agresti A, Coull BA. Approximate is better than “exact” for interval estimation of binomial proportions. Am Stat 1998;52:119–26.
   Web of Science ®Google Scholar
• Macdougall IC, Candler G, Elston O, Harchowal J. Beneficial effects of adopting an aggressive intravenous iron policy in a hemodialysis unit. Am J Kidney Dis 1999;34(4 Suppl 2):S40–6.
   PubMed Web of Science ®Google Scholar
• Besarab A, Kaiser JW, Frinak S. A study of parenteral iron regiment in hemodialysis patients. Am J Kidney Dis 1999;34:21–8.
   PubMed Web of Science ®Google Scholar
• Moist LM, Muirhead N, Wazny LD, Gallo Kl, Heidenheim AP, House AA. Erythropoietin dose requirements when converting from subcutaneous to intravenous administration among patients on hemodialysis. Ann Pharmacother 2006;40:198–203.
   PubMed Web of Science ®Google Scholar
• Raymond BC, Collins DM, Bernstein KN, Skwarchuk DE, Vercaigne LM. Erythropoietin-alpha dosage requirement in a provincial hemodialysis population: effect of switching from subcutaneous to intravenous administration. Nephron Clin Pract 2006;102:c88–92.
   PubMedGoogle Scholar
• Vercaigne LM, Collins DM, Penner SB. Conversion from subcutaneous to intravenous erythropoietin in a hemodialysis population. J Clin Pharmacol 2005;45:895–900.
   PubMed Web of Science ®Google Scholar
• Galliford JW, Malasana R, Farrington K. Switching from subcutaneous to intravenous erythropoietin α in haemodialysis patients requires a major dose increase. Nephrol Dial Transplant 2005;20:1956–62.
   PubMed Web of Science ®Google Scholar
• Pussell BA, Walker R. Dose of epoetin alfa used in haemodialysis patients when switching from subcutaneous to intravenous administration. Nephrology 2007;12:120–5.
   PubMed Web of Science ®Google Scholar
• McFarlane PA, Hillmer MP, Dacouris N. A change from subcutaneous to intravenous erythropoietin increases the cost of anemia therapy. Nephron Clin Pract 2007;107:c90–6.
   PubMedGoogle Scholar
• Messa P, Nicolini MA, Cesana B, Brezzi B, Zattera T, Magnasco A, Efficacy prospective study of different frequencies of Epo administration by i.v. and s.c. routes in renal replacement therapy patients. Nephrol Dial Transplant 2006;21:431–6.
   PubMed Web of Science ®Google Scholar
• Macdougall IC. Once-weekly erythropoietic therapy: is there a difference between the available preparations? Nephrol Dial Transplant 2002;17:2047–51.
   PubMed Web of Science ®Google Scholar
• Petersen J, Kang MS, Yeh I. The site of injection affects erythropoietin levels during dialysis. ASAIO J 1996;42:263–5.
   PubMed Web of Science ®Google Scholar
• Szczech LA, Barnhart HX, Inrig JK, Reddan DN, Sapp S, Califf RM, Secondary analysis of the CHOIR trial epoetin-α dose and achieved haemoglobin outcomes. Kidney Int 2008;74:791–8.
   PubMed Web of Science ®Google Scholar
• Macdougall IC, Tucker B, Thompson J, Tomson CRV, Baker LRI, Raine AEG. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 1996;50:1694–9.
   PubMed Web of Science ®Google Scholar
• Fishbane S, Frei GL, Maesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 1995;26:41–6.
   PubMed Web of Science ®Google Scholar
• Taylor JE, Peat N, Porter C, Morgan AG. Regular low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients. Nephrol Dial Transplant 1996;11:1079–83.
   PubMed Web of Science ®Google Scholar
• Lenga I, Lok C, Marticonera R, Hunter J, Dacouris N, Goldstein M. Role of oral iron in the management of long-term hemodialysis patients. Clin J Am Soc Nephrol 2007;2:688–93.
   PubMed Web of Science ®Google Scholar
• Jacobs C, Frei D, Perkins AC. Result of the European Survey on Anaemia Management 2003 (ESAM 2003): current status of anaemia management in dialysis patients, factors affecting epoetin dosage and changes in anaemia management over the last 5 years. Nephrol Dial Transplant 2005;20(Suppl 3):iii3–24.
   PubMedGoogle Scholar